Cardiff Oncology
San Diego, California, United States · Biotechnology, Health Care, Science And Engineering
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cance
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 31
- Industries
- Biotechnology, Health Care, Science And Engineering
- Status
- Public (CRDF)
- Website
- cardiffoncology.com
- Company page
Recent activity at Cardiff Oncology
- : Cardiff Oncology Appoints Dr. Leila Alland as Interim Chief Medical Officer
- : Cardiff Oncology Enters Settlement Agreement with Nerviano Medical Sciences (date Fundz recorded it)
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On September 14, 2026, Cardiff Oncology, Inc. and Nerviano Medical Sciences, S.r.l. entered into a Confidential Settlement Agreement and Release to resolve litigation concerning inventorship disputes of certain patents and performance issues under a prior License Agreement dated March 13, 2017. This agreement resolves the pending case known as Cardiff Oncology, Inc. v. Nerviano Medical Sciences S.r.l. in the Southern District of California. The settlement implies a significant strategic shift for Cardiff, allowing smoother development operations moving forward without the litigation's hindrance.
- : SEC 8-K (1.01): On July 14, 2026, Cardiff Oncology, Inc. entered into a securities purchase agreement with certain institutional investors to sell 8,571,429 shares of common stock and accompanying warrants at a price of $1.05 per share, along with a separate agreement to sell 721,649 shares to its insiders at $1.455 each. The gross proceeds from the offering are approximately $10.05 million, intended for working capital and general corporate purposes. The closing for these transactions occurred on July 16, 2026, with specific conditions for stockholder approval for an increase in authorized shares related to the warrants. This agreement highlights the company's strategic move to raise capital while involving both institutional and insider investors.
- : SEC 8-K (7.01):
- : SEC 8-K (1.01): On May 27, 2026, Cardiff Oncology, Inc. was informed by Nerviano Medical Sciences S.r.l. that they were terminating the License Agreement dated March 13, 2017, due to alleged material breaches by Cardiff. NMS claims that Cardiff failed to include Dr. Barbara Valsasina as a joint inventor on certain U.S. patents and did not use commercially reasonable efforts for development activities concerning their product, onvansertib. Cardiff contests the termination, asserting that it is legally ineffective and plans to continue fulfilling its obligations under the Agreement. This development comes shortly after a lawsuit was filed by Cardiff against NMS regarding the same agreement. The dispute centers on significant patent and development rights that could impact both parties' operations and future collaborations.
- : SEC 8-K (8.01): On May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.L. (NMS) in the U.S. District Court for the Southern District of California. The lawsuit disputes NMS's allegation that Cardiff materially breached their license agreement for the drug onvansertib. Cardiff seeks injunctive relief to compel NMS to fulfill its obligations under the Agreement and a declaratory judgment affirming that no breach occurred. This legal action follows NMS's assertion that Cardiff failed to name an NMS employee as a joint inventor, which Cardiff contests, emphasizing that the Agreement does not mandate such naming for solely developed inventions. The outcome may significantly impact the collaboration between the parties and Cardiff's patent rights.
- : SEC 8-K (5.02): On April 9, 2026, Cardiff Oncology, Inc. announced significant changes in its executive leadership structure. Josh Muntner has been appointed as the Chief Financial Officer, effective April 6, 2026, with a base salary of $475,000 and a 40% annual discretionary bonus, along with stock options for 486,650 shares at an exercise price of $1.58 per share. Additionally, Ajay Aggarwal, MD, MBA will become the Chief Operating Officer effective April 27, 2026, with a base salary of $490,000 and expected stock options for 400,000 shares. Moreover, Mani Mohindru, Ph.D. has been appointed as President and Chief Executive Officer, with her prior role as Interim CEO. Dr. Mohindru's compensation includes a base salary of $655,000 and significant stock options. This restructuring could impact the company's strategic direction and investor perception, as new leaders are set to take pivotal roles in the company's operations and financial stewardship.
- : SEC 8-K (5.02):
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Cardiff Oncology funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2021 | Venture | $15.0M |
| Jun 2020 | Venture | $13.5M |
| Jun 2020 | Seed | $2.5M |
| May 2020 | Seed | $810K |
| Oct 2019 | Venture | $5.0M |
Leadership
- Thomas Adams, Director
- Gary Jacob, Director
- Rodney Markin, Director
- James Armitage, Director
- Lale White, Director
- Gary Pace, Director
- John Brancaccio, Director
- Thomas Ph.D., Director
- Gary Ph.D., Director
Verified email and direct lines for Cardiff Oncology’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Cardiff Oncology files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Cardiff Oncology
- Ray Therapeutics · Biotechnology, Health Care, Science And Engineering
- Saol Therapeutics · Biotechnology, Health Care, Science And Engineering
- Electra Therapeutics · Biotechnology, Health Care, Science And Engineering
- AN2 Therapeutics · Biotechnology, Health Care, Science And Engineering
- PineTree Therapeutics · Biotechnology, Health Care, Science And Engineering
About Cardiff Oncology: questions and answers
What does Cardiff Oncology do?
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cance
Where is Cardiff Oncology headquartered?
Cardiff Oncology is headquartered in San Diego, California, United States.
How many employees does Cardiff Oncology have?
Cardiff Oncology has about 31 employees.
Has Cardiff Oncology raised funding?
Yes. Fundz has recorded 5 funding events for Cardiff Oncology. The most recent, $15.0M, was in Nov 2021.
What is the latest news on Cardiff Oncology?
On Oct 27, 2026, Cardiff Oncology Appoints Dr. Leila Alland as Interim Chief Medical Officer
Is Cardiff Oncology a public company?
Yes. Cardiff Oncology is publicly traded under the ticker CRDF.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy